MAPT and Alzheimer disease: Thus, mapping tau-PET to brain networks associated with cognitive domains typically affected in AD may allow the prediction of cognitive-domain-specific decline, to facilitate the assessment of patient-specific cognitive trajectories in clinical trials targeting tau pathology [16].